Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Authors:
- 11 May 2017
- journal article
- review article
- Published by Springer Nature in Neuropsychology Review
- Vol. 27 (4) , 305-325
Abstract
The development of methods for in vivo detection of cerebral beta amyloid retention and tau accumulation have been increasingly useful in characterizing preclinical Alzheimer’s disease (AD). While the association between these biomarkers and eventual AD has been demonstrated among cognitively intact older adults, the link between biomarkers and neurocognitive ability remains unclear. We conducted a meta-analysis to test the hypothesis that cognitively intact older adults would show statistically discernable differences in neuropsychological performance by amyloid status (amyloid negative = A-, amyloid positive = A+). We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group. Pubmed, PsychINFO, and other sources were searched for relevant articles, yielding 775 total sources. After review for inclusion/exclusion criteria, duplicates, and risk of bias, 61 studies were utilized in the final meta-analysis. Results showed A+ was associated with poorer performance in the domains of global cognitive function, memory, language, visuospatial ability, processing speed, and attention/working memory/executive functions when compared to A-. A+/N+ showed lower performances on memory measures when compared to A+/N- in secondary analyses based on a smaller subset of studies. Results support the notion that neuropsychological measures are sensitive to different stages of preclinical AD among cognitively intact older adults. Further research is needed to determine what constitutes meaningful differences in neuropsychological performance among cognitively intact older adults.Keywords
Funding Information
- National Institute on Aging (K23AG040625)
- American Federation for Aging Research (K23AG040625)
- Biogen
This publication has 91 references indexed in Scilit:
- Subjective cognitive complaints and amyloid burden in cognitively normal older individualsNeuropsychologia, 2012
- Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer diseaseNeurology, 2012
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the LiteratureJournal of Neuropathology & Experimental Neurology, 2012
- Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevantNeuroImage, 2012
- An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer diseaseAnnals of Neurology, 2011
- β-Amyloid affects frontal and posterior brain networks in normal agingNeuroImage, 2011
- Cognition, reserve, and amyloid deposition in normal agingAnnals of Neurology, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003